Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.

J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.

2.

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.

Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG.

Cell Death Dis. 2015 Jun 18;6:e1794. doi: 10.1038/cddis.2015.143.

3.

Mutagenesis and computational modeling of human G-protein-coupled receptor Y2 for neuropeptide Y and peptide YY.

Xu B, Fällmar H, Boukharta L, Pruner J, Lundell I, Mohell N, Gutiérrez-de-Terán H, Aqvist J, Larhammar D.

Biochemistry. 2013 Nov 12;52(45):7987-98. doi: 10.1021/bi400830c. Epub 2013 Oct 31.

PMID:
24111902
4.

Neuropeptide Y/peptide YY receptor Y2 duplicate in zebrafish with unique introns displays distinct peptide binding properties.

Fällmar H, Sundström G, Lundell I, Mohell N, Larhammar D.

Comp Biochem Physiol B Biochem Mol Biol. 2011 Dec;160(4):166-73. doi: 10.1016/j.cbpb.2011.08.001. Epub 2011 Aug 10.

PMID:
21855645
5.

Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.

Fällmar H, Åkerberg H, Gutiérrez-de-Terán H, Lundell I, Mohell N, Larhammar D.

Neuropeptides. 2011 Aug;45(4):293-300. doi: 10.1016/j.npep.2011.05.006. Epub 2011 Jun 22.

PMID:
21696823
6.

Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.

Akerberg H, Fällmar H, Sjödin P, Boukharta L, Gutiérrez-de-Terán H, Lundell I, Mohell N, Larhammar D.

Regul Pept. 2010 Aug 9;163(1-3):120-9. doi: 10.1016/j.regpep.2010.04.011. Epub 2010 May 13.

PMID:
20471432
7.

Identification of novel selective V2 receptor non-peptide agonists.

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.

Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.

PMID:
18761325
8.

Neuropeptide Y-family receptors Y6 and Y7 in chicken. Cloning, pharmacological characterization, tissue distribution and conserved synteny with human chromosome region.

Bromée T, Sjödin P, Fredriksson R, Boswell T, Larsson TA, Salaneck E, Zoorob R, Mohell N, Larhammar D.

FEBS J. 2006 May;273(9):2048-63.

9.

Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study.

Sjödin P, Holmberg SK, Akerberg H, Berglund MM, Mohell N, Larhammar D.

Biochem J. 2006 Jan 1;393(Pt 1):161-9. Erratum in: Biochem J. 2006 Sep 15;398(3):613.

10.

Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.

Saitton S, Del Tredici AL, Mohell N, Vollinga RC, Boström D, Kihlberg J, Luthman K.

J Med Chem. 2004 Dec 16;47(26):6595-602.

PMID:
15588094
11.

Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.

Holmberg P, Sohn D, Leideborg R, Caldirola P, Zlatoidsky P, Hanson S, Mohell N, Rosqvist S, Nordvall G, Johansson AM, Johansson R.

J Med Chem. 2004 Jul 29;47(16):3927-30.

PMID:
15267230
12.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR.

Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. Epub 2004 Jul 16.

PMID:
15258717
13.

Inhibitory effects of halothane on the thermogenic pathway in brown adipocytes: localization to adenylyl cyclase and mitochondrial fatty acid oxidation.

Ohlson KB, Shabalina IG, Lennström K, Backlund EC, Mohell N, Bronnikov GE, Lindahl SG, Cannon B, Nedergaard J.

Biochem Pharmacol. 2004 Aug 1;68(3):463-77.

PMID:
15242813
14.

Pharmacology of polymorphic variants of the human 5-HT1A receptor.

Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM.

Biochem Pharmacol. 2004 Feb 1;67(3):479-90.

PMID:
15037200
15.

Nad-299 antagonises 5-HT-stimulated and spiperone-inhibited [35S]GTPgammaS binding in cloned 5-HT1A receptors.

Jerning E, Rosqvist S, Mohell N.

J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):483-95.

PMID:
12503636
16.

Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

Croston GE, Olsson R, Currier EA, Burstein ES, Weiner D, Nash N, Severance D, Allenmark SG, Thunberg L, Ma JN, Mohell N, O'Dowd B, Brann MR, Hacksell U.

J Med Chem. 2002 Nov 7;45(23):4950-3.

PMID:
12408704
17.

The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist.

Rënyi L, Evenden JL, Fowler CJ, Jerning E, Kelder D, Lake-Bakaar D, Larsson LG, Mohell N, Sällemark M, Ross SB.

J Pharmacol Exp Ther. 2001 Dec;299(3):883-93.

PMID:
11714872
18.
19.

Serotonergic and dopaminergic activities of rigidified (R)-aporphine derivatives.

Linnanen T, Brisander M, Mohell N, Johansson AM.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):367-70.

PMID:
11212112
20.

Synthesis of novel 5-substituted 3-amino-3,4-dihydro-2H-1-benzopyran derivatives and their interactions with the 5-HT1A receptor.

Hammarberg E, Nordvall G, Leideborg R, Nylöf M, Hanson S, Johansson L, Thorberg SO, Tolf BR, Jerning E, Svantesson GT, Mohell N, Ahlgren C, Westlind-Danielsson A, Csöregh I, Johansson R.

J Med Chem. 2000 Jul 27;43(15):2837-50.

PMID:
10956192
21.

Structural analogues of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors.

Homan EJ, Kroodsma E, Copinga S, Unelius L, Mohell N, Wikström HV, Grol CJ.

Bioorg Med Chem. 1999 Jun;7(6):1111-21.

PMID:
10428381
22.

Novel derivatives of 3-(dipropylamino)chroman. Interactions with 5-HT1A and D2A receptors.

Caldirola P, Chowdhury R, Unelius L, Mohell N, Hacksell U, Johansson AM.

Bioorg Med Chem Lett. 1999 Jun 7;9(11):1583-6.

PMID:
10386940
23.

2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.

Homan EJ, Copinga S, Elfström L, van der Veen T, Hallema JP, Mohell N, Unelius L, Johansson R, Wikström HV, Grol CJ.

Bioorg Med Chem. 1998 Nov;6(11):2111-26.

PMID:
9881101
24.

Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.

Jerning E, Svantesson GT, Mohell N.

Eur J Pharmacol. 1998 Nov 6;360(2-3):219-25.

PMID:
9851589
25.

Interactions of ligands with active and inactive conformations of the dopamine D2 receptor.

Malmberg A, Mohell N, Backlund Höök B, Johansson AM, Hacksell U, Nordvall G.

Eur J Pharmacol. 1998 Apr 10;346(2-3):299-307.

PMID:
9652373
26.
27.

The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.

Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG, Rényi L, Ross SB, Wallsten C, Eriksson H, Hu PS, Jerning E, Mohell N, Westlind-Danielsson A.

J Pharmacol Exp Ther. 1997 Oct;283(1):216-25.

PMID:
9336327
28.

Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.

Höök BB, Cortizo L, Johansson AM, Westlind-Danielsson A, Mohell N, Hacksell U.

J Med Chem. 1996 Sep 27;39(20):4036-43.

PMID:
8831769
29.

Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin.

Yu H, Liu Y, Malmberg A, Mohell N, Hacksell U, Lewander T.

Eur J Pharmacol. 1996 May 15;303(3):151-62.

PMID:
8813561
30.
31.

Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?

Jackson DM, Mohell N, Bengtsson A, Malmberg A.

Eur J Pharmacol. 1995 Aug 25;282(1-3):137-44.

PMID:
7498268
32.
33.

Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors.

Halldin C, Farde L, Högberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG.

J Nucl Med. 1995 Jul;36(7):1275-81.

34.
35.

Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.

Jackson DM, Mohell N, Georgiev J, Bengtsson A, Larsson LG, Magnusson O, Ross SB.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Feb;351(2):146-55.

PMID:
7539523
36.

Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists.

Liu Y, Yu H, Mohell N, Nordvall G, Lewander T, Hacksell U.

J Med Chem. 1995 Jan 6;38(1):150-60.

PMID:
7530773
37.
38.

Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors.

Malmberg A, Nordvall G, Johansson AM, Mohell N, Hacksell U.

Mol Pharmacol. 1994 Aug;46(2):299-312.

PMID:
8078492
39.

Thermogenesis in brown adipocytes is inhibited by volatile anesthetic agents. A factor contributing to hypothermia in infants?

Ohlson KB, Mohell N, Cannon B, Lindahl SG, Nedergaard J.

Anesthesiology. 1994 Jul;81(1):176-83.

PMID:
8042786
40.

Preclinical findings with new antipsychotic agents: what makes them atypical?

Jackson DM, Ryan C, Evenden J, Mohell N.

Acta Psychiatr Scand Suppl. 1994;380:41-8. Review.

PMID:
7914047
41.

Physiological desensitization of beta 3-adrenergic responses in brown fat cells: involvement of a postreceptor process.

Unelius L, Bronnikov G, Mohell N, Nedergaard J.

Am J Physiol. 1993 Nov;265(5 Pt 1):C1340-8.

PMID:
7902009
42.

Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

Mohell N, Sällemark M, Rosqvist S, Malmberg A, Högberg T, Jackson DM.

Eur J Pharmacol. 1993 Jul 6;238(1):121-5.

PMID:
8405075
43.

Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.

Malmberg A, Jackson DM, Eriksson A, Mohell N.

Mol Pharmacol. 1993 May;43(5):749-54.

PMID:
8099194
44.

Cold acclimation induces desensitization to adenosine in brown fat cells without changing receptor binding.

Unelius L, Mohell N, Nedergaard J.

Am J Physiol. 1990 May;258(5 Pt 1):C818-26.

PMID:
1692190
47.

Distinction between mechanisms underlying alpha 1- and beta-adrenergic respiratory stimulation in brown fat cells.

Mohell N, Connolly E, Nedergaard J.

Am J Physiol. 1987 Aug;253(2 Pt 1):C301-8.

PMID:
3618763
48.
49.
50.

Increased alpha 1-adrenergic receptor density in brown adipose tissue of cold-acclimated rats and hamsters.

Raasmaja A, Mohell N, Nedergaard J.

Eur J Pharmacol. 1984 Nov 27;106(3):489-98.

PMID:
6097459

Supplemental Content

Loading ...
Support Center